期刊
TRENDS IN IMMUNOLOGY
卷 42, 期 1, 页码 59-75出版社
CELL PRESS
DOI: 10.1016/j.it.2020.11.001
关键词
-
类别
资金
- Spanish Ministry of Science and Innovation (AEI/FEDER, UE) [SAF2017-88086-R]
- RESTORE project (European Union's Horizon 2020 research and innovation programme) [779316]
- Spanish projects [PI17/01521, PI20/01313]
- ISCIII-Subdireccion General de Evaluacion
- Fondo Europeo de Desarrollo Regional (FEDER)
- Accion Estrategica en Salud [IFI17/00034]
- Fondo Social Europeo
- INsTRuCT Consortium, focused on developing innovative myeloid regulatory cell (MRC)-based immunotherapies
- European Union
- H2020 Societal Challenges Programme [779316] Funding Source: H2020 Societal Challenges Programme
Dendritic cells play a crucial role in activating T cells and can acquire tolerogenic functions through various stimuli. Research shows that tolerogenic dendritic cells have potential clinical applications in treating inflammatory diseases.
Dendritic cells (DCs), the most efficient antigen-presenting cells, are necessary for the effective activation of naive T cells. DCs can also acquire tolerogenic functions in vivo and in vitro in response to various stimuli, including interleukin (IL)-10, transforming growth factor (TGF)-beta, vitamin D3, corticosteroids, and rapamycin. In this review, we provide a wide perspective on the regulatory mechanisms, including crosstalk with other cell types, downstream signaling pathways, transcription factors, and epigenetics, underlying the acquisition of tolerogenesis by DCs, with a special focus on human studies. Finally, we present clinical assays targeting, or based on, tolerogenic DCs in inflammatory diseases. Our discussion provides a useful resource for better understanding the biology of tolerogenic DCs and their manipulation to improve the immunological fitness of patients with certain inflammatory conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据